CNS DRUGS

Scope & Guideline

Empowering Research for Better CNS Therapeutics

Introduction

Welcome to your portal for understanding CNS DRUGS, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN1172-7047
PublisherADIS INT LTD
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 1994 to 2024
AbbreviationCNS DRUGS / CNS Drugs
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND

Aims and Scopes

CNS Drugs focuses on the pharmacological treatment of central nervous system disorders, emphasizing the development of new therapies and their clinical applications. The journal aims to provide comprehensive insights into a wide range of neurological and psychiatric conditions, fostering an understanding of drug mechanisms, efficacy, and safety.
  1. Pharmacological Treatments for CNS Disorders:
    The journal publishes research on the pharmacological management of various CNS disorders, including epilepsy, depression, schizophrenia, multiple sclerosis, and neurodegenerative diseases. This includes both established medications and emerging therapeutic strategies.
  2. Clinical Trials and Real-World Evidence:
    CNS Drugs emphasizes the importance of clinical trials and real-world evidence in understanding the effectiveness and safety of CNS drugs. Many papers discuss trial results, observational studies, and meta-analyses to inform clinical practice.
  3. Mechanisms of Action and Drug Development:
    The journal explores the underlying mechanisms of action of CNS drugs, contributing to the understanding of how these drugs affect neurological and psychiatric functions and guiding the development of novel therapies.
  4. Patient-Centric Approaches and Outcomes:
    Research focusing on patient outcomes, quality of life, and the tolerability of treatments is a core area, addressing how pharmacological therapies impact patients' daily lives.
  5. Emerging Therapies and Innovations:
    CNS Drugs highlights innovative therapies, including new drug formulations, combination therapies, and the use of biologics, reflecting the journal's commitment to advancing treatment options in the field.
CNS Drugs has identified several emerging trends and themes in recent publications, reflecting the evolving landscape of CNS pharmacotherapy. These trends indicate a shift towards innovative treatment strategies and a deeper understanding of CNS disorders.
  1. Psychedelic-Assisted Therapies:
    The exploration of psychedelic drugs for therapeutic use in treating various mental health disorders has gained traction, highlighting a renewed interest in these compounds and their potential benefits.
  2. Combination Therapies:
    There is an increasing emphasis on combination therapies, particularly in the treatment of conditions like Alzheimer's disease and depression, reflecting a trend towards more comprehensive management strategies.
  3. Biologics and Targeted Therapies:
    The rise of biologic therapies and targeted treatments for conditions such as multiple sclerosis and neurodegenerative diseases indicates a paradigm shift in how these disorders are treated.
  4. Patient-Centric Research:
    A growing focus on patient perspectives, outcomes, and quality of life in clinical research reflects an increasing awareness of the importance of patient-centric approaches in CNS drug development.
  5. Real-World Evidence and Data Utilization:
    The use of real-world evidence in understanding treatment effectiveness and safety is becoming more prominent, emphasizing the need for data that reflects everyday clinical practice.

Declining or Waning

While CNS Drugs continues to address a wide array of topics, certain areas have shown a decrease in publication frequency or intensity. This may reflect changing research priorities or advancements in treatment options that have rendered some topics less prevalent.
  1. Traditional Antiseizure Medications:
    Research focused on older antiseizure medications has become less prominent, likely due to the emergence of newer drugs with improved efficacy and safety profiles. The shift signifies a move towards investigating novel therapies rather than re-evaluating established treatments.
  2. Single-Agent Psychiatric Treatments:
    There is a noticeable decline in studies exclusively evaluating single-agent treatments for psychiatric disorders, as the focus has shifted towards combination therapies and personalized medicine approaches.
  3. Long-Term Side Effects of Established Treatments:
    Although important, studies specifically addressing long-term side effects of traditional treatments are appearing less frequently, possibly due to a growing emphasis on efficacy and immediate clinical outcomes.
  4. Pharmacological Management of Rare CNS Disorders:
    Research on pharmacological treatments for rare CNS conditions has decreased, possibly due to the limited patient populations and funding opportunities, leading to a focus on more common conditions.
  5. Neuropharmacology of Older Drug Classes:
    Topics related to the neuropharmacology of older drug classes, such as first-generation antipsychotics, are seeing reduced attention as the field progresses towards newer medications with novel mechanisms of action.

Similar Journals

CNS & Neurological Disorders-Drug Targets

Advancing the Frontiers of Neurological Research
Publisher: BENTHAM SCIENCE PUBLISSN: 1871-5273Frequency: 8 issues/year

CNS & Neurological Disorders-Drug Targets is a distinguished journal that focuses on contemporary research and advancements in the realms of neurology, pharmacology, and drug development. Published by Bentham Science Publishers, this journal serves as an essential platform for researchers, professionals, and students interested in the intricate workings of the central nervous system and the evolving strategies to target neurological disorders through pharmacological innovations. With a robust impact factor reflecting its academic relevance, CNS & Neurological Disorders-Drug Targets is categorized in the Q2 quartile for both Medicine (miscellaneous) and Pharmacology, and Q3 for Neuroscience in the 2023 rankings. The journal's Scopus rankings further reinforce its authority, positioning it within the top half of its categories. Operating out of the United Arab Emirates, the journal has been a loyal contributor to the scientific discourse since its inception in 2006 and will continue until at least 2024, ensuring a dynamic channel for the latest findings and reviews in this vital field. As an open-access publication, it prioritizes accessibility, thus fostering a wider impact among scholars and practitioners alike, making it a valuable resource for all stakeholders in neurological and pharmacological research.

Pain and Therapy

Advancing the Frontiers of Pain Management.
Publisher: SPRINGER INT PUBL AGISSN: 2193-8237Frequency: 2 issues/year

Pain and Therapy is a prestigious, peer-reviewed journal published by SPRINGER INTERNATIONAL PUBLISHING AG that has been a beacon of research in the field of pain management and neurology since its inception in 2012. With an ISSN of 2193-8237 and an E-ISSN of 2193-651X, this open access journal facilitates the dissemination of high-quality research to a global audience. Recognized within the top Q1 quartile for Anesthesiology and Pain Medicine, and the Q2 category for Clinical Neurology, it ranks impressively within the Scopus indexing, positioned at #20/136 in its primary category, demonstrating an 85th percentile standing. The journal's commitment to open access enhances its impact, allowing researchers, clinicians, and students to explore and contribute to critical developments in pain therapy and management. The convergence of cutting-edge research and innovative therapeutic strategies makes Pain and Therapy an essential resource for anyone dedicated to advancing knowledge in this vital field.

American Journal of Cardiovascular Drugs

Pioneering Research in Cardiovascular Pharmacology
Publisher: ADIS INT LTDISSN: 1175-3277Frequency: 6 issues/year

American Journal of Cardiovascular Drugs, published by ADIS INT LTD, is a premier peer-reviewed journal dedicated to the field of cardiology and cardiovascular medicine. With an ISSN of 1175-3277 and an E-ISSN of 1179-187X, this esteemed journal has established itself as a crucial platform for disseminating high-quality research since its inception in 2001. It holds a significant position in its domain, ranking in the second quartile (Q2) across several categories including Cardiology, Medicine (miscellaneous), and Pharmacology (medical) for the year 2023. With its Scopus ranks placing it in the 81st percentile for Cardiology and 77th percentile for Pharmacology, the journal is highly regarded among professionals, researchers, and students alike. While it is not an open-access journal, its comprehensive articles and systematic reviews provide an in-depth exploration of cardiovascular drug therapy, therapeutic advancements, and clinical practices, making it an invaluable resource for anyone invested in the future of cardiovascular health.

JOURNAL OF PSYCHOPHARMACOLOGY

Transforming Understanding of Psychopharmacological Effects
Publisher: SAGE PUBLICATIONS LTDISSN: 0269-8811Frequency: 12 issues/year

JOURNAL OF PSYCHOPHARMACOLOGY, published by SAGE Publications Ltd, is a leading peer-reviewed journal that explores the intricate dynamics of pharmacological interventions in mental health and psychiatry. With an ISSN of 0269-8811 and an E-ISSN of 1461-7285, this esteemed journal has established its reputation in the field since its inception in 1987, converging research excellence into 2024. Recognized as a Q1 journal in various categories including Medicine (miscellaneous), Pharmacology, and Psychiatry and Mental Health, it ranks impressively within the top percentile in Scopus, standing at #64 out of 567 in Psychiatry and Mental Health, and #31 out of 272 in Medical Pharmacology. The journal serves as a vital resource for researchers, professionals, and students, providing insightful articles that advance the understanding of psychopharmacological effects and innovations. Although it does not offer open access, the journal's extensive research and impactful findings make it essential reading for anyone engaged in the field. For those seeking to stay at the forefront of psychopharmacology, the JOURNAL OF PSYCHOPHARMACOLOGY is an invaluable asset.

NEUROPHARMACOLOGY

Connecting Neuroscience and Pharmacology for Tomorrow's Discoveries
Publisher: PERGAMON-ELSEVIER SCIENCE LTDISSN: 0028-3908Frequency: 16 issues/year

NEUROPHARMACOLOGY, published by PERGAMON-ELSEVIER SCIENCE LTD, is a prestigious journal in the field of neuroscience and pharmacology, with a distinguished history dating back to 1962. With an ISSN of 0028-3908 and an E-ISSN of 1873-7064, the journal serves as a dynamic platform for the latest research that explores the intricate relationships between pharmacological agents and neural processes. Positioned in the Q1 quartile in both Cellular and Molecular Neuroscience and Pharmacology, it is recognized for its significant impact in the scientific community, boasting Scopus rankings of #36 in Pharmacology and #16 in Cellular and Molecular Neuroscience, underscoring its excellence and relevance. Although not an open access publication, its contributions are pivotal for researchers, professionals, and students sought to understand the complexities of neuropharmacological interactions. The journal aims to disseminate groundbreaking research findings, reviews, and perspectives that expand the frontiers of knowledge in the fields, making it an essential resource for anyone involved in neuroscience and pharmacology research.

Neurology and Therapy

Exploring Innovations in Neurology and Therapeutic Solutions
Publisher: SPRINGER LONDON LTDISSN: 2193-8253Frequency: 2 issues/year

Neurology and Therapy, published by SPRINGER LONDON LTD, stands as a pivotal platform for researchers and practitioners in the field of neurology and its therapeutic applications. This Open Access journal, active since 2012, facilitates the dissemination of innovative studies and cutting-edge findings aimed at improving neurological health. With an impressive ranking in the 2023 Scopus Rankings, where it holds a Q2 category in Neurology and a Q1 category in Clinical Neurology, it underscores its prominence in advancing neurological research. The journal's intriguing scope encompasses a wide-ranging exploration of neurological disorders, treatment methodologies, and healthcare strategies, making it a valuable resource for those vested in enhancing patient outcomes. With an appealing average impact factor, readers are encouraged to dive into the latest advancements and engage with the scholarly discussions that are shaping the future of neurology.

ANTIVIRAL THERAPY

Transforming the landscape of antiviral pharmacology.
Publisher: SAGE PUBLICATIONS LTDISSN: 1359-6535Frequency: 8 issues/year

ANTIVIRAL THERAPY is a prominent academic journal dedicated to the field of infectious diseases and pharmacology, published by SAGE Publications Ltd in the United Kingdom. Since its inception in 1996, this journal has become an essential platform for disseminating cutting-edge research and innovative therapeutic approaches for viral infections, making significant contributions to advancements in medical science. With an HIndex indicating the quality and influence of its published work, ANTIVIRAL THERAPY holds prestigious rankings in its categories, including Q3 in Infectious Diseases and Pharmacology as of 2023. While it currently does not offer open access, the journal provides valuable insights that are crucial for researchers, healthcare professionals, and students engaged in antiviral research and treatment strategies. As it converges towards 2024, the journal continues to play a vital role in shaping the understanding and management of viral diseases, making it a critical resource for anyone involved in this important field of study.

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Transforming Clinical Practices with Groundbreaking Psychopharmacology Studies
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0271-0749Frequency: 6 issues/year

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, an esteemed publication from Lippincott Williams & Wilkins, serves as a vital resource in the fields of pharmacology and psychiatry. With a notable Q2 ranking in both the medical pharmacology and psychiatry categories, this journal facilitates the dissemination of significant findings related to psychopharmacological research, clinical practices, and advancements in mental health treatment. The journal has been committed to publishing high-quality, peer-reviewed articles since its inception in 1981, covering a wide scope of topics crucial for professionals, researchers, and students alike. With a current impact factor and burgeoning interest from the academic community, the JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY is essential for anyone engaged in the study or practice of clinical psychopharmacology, providing insights that shape contemporary psychiatric medication strategies and improve patient outcomes. For access, please refer to the official publication channels.

Therapeutic Advances in Neurological Disorders

Transforming understanding into effective therapies for neurological challenges.
Publisher: SAGE PUBLICATIONS LTDISSN: 1756-2856Frequency: 1 issue/year

Therapeutic Advances in Neurological Disorders, published by SAGE Publications Ltd, is a leading open access journal dedicated to the advancement of knowledge in the field of neurology. Since its inception in 2008, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for the dissemination of high-quality research that improves the understanding and treatment of neurological disorders. With a commendable impact factor and ranked Q1 in multiple categories, including Neurology and Pharmacology for 2023, it exemplifies excellence in scholarly contributions. The journal's Scope encompasses a wide array of topics, providing insights that are pivotal for clinical practice and pharmacological development. Additionally, with its commitment to open access since 2017, Therapeutic Advances in Neurological Disorders ensures that its research reaches a global audience, fostering collaboration and innovation in neurological science.

JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY

Pioneering research that shapes the landscape of pediatric psychopharmacology.
Publisher: MARY ANN LIEBERT, INCISSN: 1044-5463Frequency: 10 issues/year

JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, published by MARY ANN LIEBERT, INC, stands as a premier academic journal dedicated to advancing the field of pediatric psychopharmacology. With a rich history of publication spanning from 1990 to 2024, this journal presents cutting-edge research that informs clinical practices and policy decisions impacting the mental health of children and adolescents. Ranked in the Q2 category for both Pediatrics, Perinatology and Child Health and Pharmacology (medical) as of 2023, it reflects its critical contribution to these fields, along with a respectable Q3 status in Psychiatry and Mental Health. Researchers and practitioners benefit from the journal's rigorous peer-reviewed articles, which delve into the efficacy, safety, and ethical implications of pharmacological treatments tailored for young populations. Although the journal does not currently offer Open Access, it remains a vital resource for anyone engaged in child and adolescent health research and treatment strategies. Its commitment to fostering dialogue and innovation in psychopharmacology ensures its pivotal role in shaping future standards and practices in this essential area of medical science.